Merck closes license agreement for LM-299

Merck will record a pre-tax charge relating to the upfront payment of $588 million

Cipla launches India's first inhalable insulin ‘Afrezza’

Afrezza, developed by MannKind Corporation in the USA, offers a needle-free, rapid-acting insulin option for diabetes management

Merck to discontinue KeyVibe and Keyform clinical trials

Merck has also decided to end the favezelimab clinical development program

Bayer announces positive topline resukts for Aflibercept 8 mg in phase III study

Demonstrates vision gains with extended treatment intervals in retinal vein occlusion

Genpharmasec enters into supper stockist agreement with Amneal Healthcare

NTC presents positive results from Phase II Mirakle study evaluating an innovative drug for bacterial conjunctivitis

Despite NTC014, due to its simplified therapeutic regimen, has been administered at a lower posology than the antibiotic comparator

FDA approves BridgeBio’s Attruby for ATTR-CM treatment

Attruby is the first and only approved product with a label specifying near-complete stabilization of TTR

European Commission approves Pfizer’s HYMPAVZI for treatment of severe Hemophilia A or B without inhibitors

HYMPAVZI’s approval is based on Phase 3 study results demonstrating non-inferiority and superiority compared to routine prophylaxis in eligible patients with hemophilia A or B without inhibitors

Pfizer appoints Chris Boshoff as Chief Scientific Officer and President, Research & Development

Roger Dansey to become Interim Chief Oncology Officer and Johanna Bendell to join Pfizer as Oncology Chief Development Officer

Indegene announces new Center in Hyderabad

With 6 operation hubs and 18 offices across North America, Europe, and Asia, Indegene’s client base includes the world’s top 20 biopharma companies